SG11202000523PA - Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia - Google Patents
Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemiaInfo
- Publication number
- SG11202000523PA SG11202000523PA SG11202000523PA SG11202000523PA SG11202000523PA SG 11202000523P A SG11202000523P A SG 11202000523PA SG 11202000523P A SG11202000523P A SG 11202000523PA SG 11202000523P A SG11202000523P A SG 11202000523PA SG 11202000523P A SG11202000523P A SG 11202000523PA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- treating
- compounds
- methods
- lymphoblastic leukemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539012P | 2017-07-31 | 2017-07-31 | |
| PCT/US2018/044659 WO2019028055A1 (en) | 2017-07-31 | 2018-07-31 | Compounds, compositionals, and methods for treating t-cell acute lymphoblastic leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000523PA true SG11202000523PA (en) | 2020-02-27 |
Family
ID=63245072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000523PA SG11202000523PA (en) | 2017-07-31 | 2018-07-31 | Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11459306B2 (en) |
| EP (1) | EP3661924A1 (en) |
| JP (1) | JP2020529418A (en) |
| CN (1) | CN111386264A (en) |
| AU (2) | AU2018309739B2 (en) |
| BR (1) | BR112020001949A2 (en) |
| CA (1) | CA3071123A1 (en) |
| IL (1) | IL272067A (en) |
| RU (1) | RU2020108454A (en) |
| SG (1) | SG11202000523PA (en) |
| WO (1) | WO2019028055A1 (en) |
| ZA (1) | ZA202204657B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3119397T3 (en) | 2014-03-19 | 2022-03-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of PI3K-gamma-mediated disorders |
| KR20180058741A (en) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | Solid form of isoquinolines, a process for their preparation, compositions comprising them and methods for using them |
| CN113512042B (en) * | 2020-04-09 | 2024-06-11 | 成都赜灵生物医药科技有限公司 | Substituted quinazoline-4-ketone compound and preparation method and application thereof |
| WO2023091785A1 (en) * | 2021-11-22 | 2023-05-25 | Secura Bio, Inc. | Methods for treating peripheral t-cell lymphoma |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US6632789B1 (en) | 1994-04-29 | 2003-10-14 | The United States Of America As Represented By The Secretary Of The Navy | Methods for modulating T cell responses by manipulating intracellular signal transduction |
| RU2001128165A (en) | 1999-03-18 | 2004-03-27 | Эксикон А/С (Dk) | IDENTIFICATION OF MUTATIONS IN GENES BY SPECIFIC LNA PRIMERS |
| PT1939203E (en) * | 2000-04-25 | 2015-02-04 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform |
| US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| CA2528938A1 (en) | 2003-06-13 | 2005-02-24 | Zentaris Gmbh | Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof |
| US20050182005A1 (en) | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
| ES2605792T3 (en) * | 2004-05-13 | 2017-03-16 | Icos Corporation | Quinazolinone used as a human phosphatidylinositol 3-kinase delta inhibitor |
| EP1755609A1 (en) | 2004-05-25 | 2007-02-28 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
| CN101031658A (en) | 2004-05-26 | 2007-09-05 | 罗塞塔金诺米克斯有限公司 | Viral and viral associated mirnas and uses thereof |
| US7825229B2 (en) | 2005-03-25 | 2010-11-02 | Rosetta Genomics Ltd. | Lung cancer-related nucleic acids |
| US7642348B2 (en) | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
| WO2006126040A1 (en) | 2005-05-25 | 2006-11-30 | Rosetta Genomics Ltd. | Bacterial and bacterial associated mirnas and uses thereof |
| EP1984399A4 (en) | 2006-02-10 | 2010-03-03 | Univ California | Transducible delivery of sirna by dsrna binding domain fusions to ptd/cpps |
| NZ578162A (en) | 2006-12-07 | 2011-12-22 | Genentech Inc | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| US8193182B2 (en) * | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US9492449B2 (en) * | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| CN104042618B (en) | 2008-11-13 | 2018-02-16 | 吉利德卡利斯托加公司 | The treatment of malignant hematologic disease |
| WO2012121953A1 (en) | 2011-03-08 | 2012-09-13 | The Trustees Of Columbia University In The City Of New York | Methods and pharmaceutical compositions for treating lymphoid malignancy |
| AU2012302197B2 (en) * | 2011-08-29 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| US20130143902A1 (en) * | 2011-12-02 | 2013-06-06 | Gilead Calistoga Llc | Compositions and methods of treating a proliferative disease with a quinazolinone derivative |
| RS58023B2 (en) * | 2012-11-01 | 2021-12-31 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014100767A1 (en) * | 2012-12-21 | 2014-06-26 | Gilead Calistoga Llc | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
| WO2014128612A1 (en) * | 2013-02-20 | 2014-08-28 | Novartis Ag | Quinazolin-4-one derivatives |
| WO2015168079A1 (en) * | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
| CA2953820A1 (en) * | 2014-06-24 | 2015-12-30 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
-
2018
- 2018-07-31 JP JP2020505408A patent/JP2020529418A/en active Pending
- 2018-07-31 EP EP18756082.6A patent/EP3661924A1/en not_active Withdrawn
- 2018-07-31 WO PCT/US2018/044659 patent/WO2019028055A1/en unknown
- 2018-07-31 BR BR112020001949-6A patent/BR112020001949A2/en not_active Application Discontinuation
- 2018-07-31 AU AU2018309739A patent/AU2018309739B2/en not_active Ceased
- 2018-07-31 CA CA3071123A patent/CA3071123A1/en not_active Abandoned
- 2018-07-31 CN CN201880057217.2A patent/CN111386264A/en active Pending
- 2018-07-31 RU RU2020108454A patent/RU2020108454A/en unknown
- 2018-07-31 SG SG11202000523PA patent/SG11202000523PA/en unknown
- 2018-07-31 US US16/633,074 patent/US11459306B2/en active Active
-
2020
- 2020-01-15 IL IL272067A patent/IL272067A/en unknown
-
2022
- 2022-04-06 AU AU2022202286A patent/AU2022202286A1/en not_active Abandoned
- 2022-04-26 ZA ZA2022/04657A patent/ZA202204657B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020108454A (en) | 2021-09-02 |
| US11459306B2 (en) | 2022-10-04 |
| AU2018309739A1 (en) | 2020-02-20 |
| CN111386264A (en) | 2020-07-07 |
| ZA202204657B (en) | 2022-07-27 |
| EP3661924A1 (en) | 2020-06-10 |
| AU2022202286A1 (en) | 2022-04-28 |
| CA3071123A1 (en) | 2019-02-07 |
| US20200165211A1 (en) | 2020-05-28 |
| WO2019028055A1 (en) | 2019-02-07 |
| BR112020001949A2 (en) | 2020-07-28 |
| AU2018309739A8 (en) | 2020-10-08 |
| AU2018309739B2 (en) | 2022-01-27 |
| IL272067A (en) | 2020-03-31 |
| RU2020108454A3 (en) | 2022-02-02 |
| JP2020529418A (en) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272089B1 (en) | Compounds, compositions and methods | |
| IL288816A (en) | Aminobenzazepine compounds, immunoconjugates, and uses thereof | |
| IL277435A (en) | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma | |
| IL272844A (en) | Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers | |
| SI3676297T1 (en) | Compounds, compositions and methods | |
| IL285302A (en) | Compounds, compositions and methods | |
| ZA202204657B (en) | Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia | |
| IL267451A (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| EP3592841A4 (en) | Methods and compositions for treating cancers using antisense | |
| EP3847283A4 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| PT3552017T (en) | Compounds, compositions and methods | |
| IL271728A (en) | Agents, uses and methods for treatment | |
| ZA201907283B (en) | Compositions, devices and methods for treating autism | |
| IL287120A (en) | Compounds, compositions and methods | |
| EP3294301A4 (en) | Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same | |
| EP3544609A4 (en) | Compositions, devices and methods for treating obsessive-compulsive disorder | |
| EP3615020A4 (en) | Methods, agents, and compositions for the treatment of acute myeloid leukemia | |
| GB201805089D0 (en) | Composition, method and use | |
| GB201805016D0 (en) | Composition, method and use | |
| ZA202004349B (en) | Fluoralkenyl compounds, process for preparation and use thereof | |
| IL269769B (en) | Compounds, composition and uses thereof for treating cancer | |
| GB201705124D0 (en) | Composition, method and use | |
| IL282692A (en) | Madrasin-derivative compounds, composition and uses thereof for treating cancer | |
| IL274529A (en) | Compounds, compositions, and methods for treating and/or preventing periodontal disease | |
| IL270505B1 (en) | Compounds, compositions and methods |